# Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

> **NCT05947825** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Combination of sitagliptin+ gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT05947825
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-30
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947825, "Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05947825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*